All In MedTech

Device Trial Radar · NCT05881733

Effect of a Bigger Cryoballoon on the Total Antral Lesion Size: Evaluation of POLARx FIT

Last checked: Nov 20, 2026Latest source record: Dec 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

20

Actual

Start

Oct 2, 2023

Primary completion

Apr 29, 2024

Study completion Apr 23, 2025

Sponsor

Lead sponsor
Erasmus Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Boston Scientific Corporation
First posted
May 31, 2023

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The investigators will prospectively evaluate the extent of antral lesion created by the 31 mm balloon size of a novel cryoballoon catheter (POLARx FIT). In 20 patients with paroxysmal atrial fibrillation, the investigators will perform pre- and post-ablation high-definition 3D maps to quantify the extent of lesion created by the 31 mm POLARx FIT cryoballoon.

Conditions

  • Atrial Fibrillation

Interventions

  • POLARx FIT cryoballoonDevice

    Patients will undergo cryoablation with the 31 mm balloon size of the POLARx FIT cryoballoon.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Ablated Left Atrial Posterior Wall With a 31 mm Balloon Size POLARx FITTime frame: Interprocedural (directly after cryoablation)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Erasmus Medical Center

    Rotterdam, South Holland, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.